Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are both FDA-approved specifically for weight management in adults with obesity or overweight with a weight-related condition regardless of whether diabetes is present
In cases of significant nausea, pharmacologic interventions such as prochlorperazine may be used as needed and are preferred over ondansetron
Currently, the FDA has officially approved a higher-dose formulation of semaglutide called Wegovy specifically for chronic weight management in adults who are overweight or obese, even if they do not have diabetes
It depends on your progress and goals
The American Heart Association specifically recommends consuming a diet that emphasizes intake of vegetables, fruits, whole grains, legumes, and healthy protein
These therapies do far more than help patients lose weight